Investigation Report on China’s Octreotide Market 2021-2025

$2,600$3,900

In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Octreotide in the Chinese market decreased to CNY690 million, a year-on-year decrease of 3.8%.

Clear

Description

Octreotide is a derivative of artificially modified natural somatostatin, which is an octapeptide. Its physiological effects include inhibiting growth hormone function, inhibiting the secretion of gastric acid, pancreatic enzymes, glucagon and insulin, reducing visceral blood flow, reducing gastrointestinal motility, etc. It is clinically used for emergency treatment of esophageal-varices bleeding, treatment of acromegaly and treatment related to gastrointestinal endocrine tumors. Its product SANDOSTATIN was developed by Novartis Pharma Schweiz AG and was approved to enter the Chinese market in 2003. Since then, some generic drugs have also been listed in the Chinese market. By 2020, there are several manufacturers in the Chinese Octreotide market, among which Novartis Pharma Schweiz AG accounts for the most market share.

According to CRI’s market research, the sales value of Octreotide in the Chinese market from 2016 to 2019 were relatively stable. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Octreotide in the Chinese market decreased to CNY690 million, a year-on-year decrease of 3.8%. From 2016 to 2020, the CAGR of Octreotide sales value in the Chinese market is -0.48%.

CRI expects that with the relief of COVID-19, the sales value of Octreotide in the Chinese market will have a restorative growth from 2021 to 2025. In addition, compared with similar drugs, Octreotide has a longer action time, not only can extensively inhibit the secretion of digestive juice, but also promotes the absorption of digestive juice by the intestinal mucosa. Based on these advantages, the sales value and sales volume of Octreotide still has room to rise. At the same time, in recent years, the pace of life of Chinese residents has accelerated, and irregular eating habits have increased the prevalence of various gastrointestinal diseases. Therefore, the demand for Octreotide will continue to expand and its sales value will continue to grow from 2021 to 2025.

Topics Covered:

  • -The impact of COVID-19 on China’s Octreotide market
  • – Sales value of China’s Octreotide 2016-2020
  • – Competitive landscape of China’s Octreotide market
  • – Prices of Octreotide in China
  • – Prices of Octreotide in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Octreotide market
  • – Prospect of China’s Octreotide market from 2021 to 2025

Additional information

Publisher

Date Published

Pages

Charts

Format

Table of Contents

1 Relevant Concepts of Octreotide

  • 1.1 Indications for Octreotide
  • 1.2 Development of Octreotide in China
  • 1.3 Governmental Approval of Octreotide in China
  • 1.4 The Impact of COVID-19 on Octreotide Sales in China

 

2 Sales of Octreotide in China, 2016-2020

  • 2.1 Sales Value of Octreotide
  • 2.1.1 Overall Sales Value
  • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Octreotide
  • 2.2.1 Overall Sales Volume
  • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Octreotide by Dosage Form in China, 2016-2020
  • 2.3.1 Injection
  • 2.3.2 Analysis of Other Dosage Form

 

3 Analysis of Major Octreotide Manufacturers in China in 2020

  • 3.1 Analysis of Market Share of Major Octreotide Manufacturers
  • 3.1.1 Investigation on Market Share by Sales Value
  • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Novartis Pharma Schweiz AG
  • 3.2.1 Enterprise Profile
  • 3.2.2 Sales of SANDOSTATIN (Novartis Pharma Schweiz AG’s Octreotide) in China
  • 3.3  Sandoz GmbH/Abbott Biologicals B.V.
  • 3.3.1 Enterprise Profile
  • 3.3.2 Sales of SANDOSTATIN LAR (Sandoz GmbH/Abbott Biologicals B.V.’s Octreotide) in China
  • 3.4 Sinopharm Yixin Pharmaceutical Co., Ltd.
  • 3.4.1 Enterprise Profile
  • 3.4.2 Sales of Lierning (Sinopharm Yixin Pharmaceutical Co., Ltd.’s Octreotide) in China
  • 3.5 Shanghai No. 1 Biochemical & Pharmaceutical Co. Ltd.
  • 3.5.1 Enterprise Profile
  • 3.5.2 Sales of Shengaoding (Shanghai No. 1 Biochemical & Pharmaceutical Co. Ltd.’s Octreotide) in China
  • 3.6 Suzhou Tianma Pharma Group Tianji Bio-pharmaceutical Co., Ltd.
  • 3.6.1 Enterprise Profile
  • 3.6.2 Sales of Anli (Suzhou Tianma Pharma Group Tianji Bio-pharmaceutical Co., Ltd.’s Octreotide) in China

 

4 Prices of Octreotide for Different Manufacturers in China, 2020-2021

  • 4.1 Novartis Pharma Schweiz AG (SANDOSTATIN)
  • 4.2 Sandoz GmbH/Abbott Biologicals B.V. (SANDOSTATIN LAR)
  • 4.3 Sinopharm Yixin Pharmaceutical Co., Ltd. (Lierning)
  • 4.4 Shanghai No. 1 Biochemical & Pharmaceutical Co. Ltd. (Shengaoding)
  • 4.5 Suzhou Tianma Pharma Group Tianji Bio-pharmaceutical Co., Ltd. (Anli)

 

5 Prospect of Chinese Octreotide Market, 2021-2025

  • 5.1 Influential Factors of Chinese Octreotide Market Development
  • 5.1.1 The Impact of COVID-19 on Chinese Octreotide Market
  • 5.1.2 Market Drivers and Opportunities
  • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

 

List of Charts

  • Chart Patent Information About Octreotide Injection Registration in China
  • Chart Sales Value of Octreotide Injection over the World
  • Chart Sales Value of Octreotide Injection in China, 2016-2020
  • Chart Sales Value of Octreotide Injection in China by Region, 2016-2020
  • Chart Sales Volume of Octreotide Injection in China, 2016-2020
  • Chart Sales Volume of Octreotide Injection in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Octreotide Injection Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of SANDOSTATIN in China, 2016-2020
  • Chart Sales Value and Volume of SANDOSTATIN LAR in China, 2016-2020
  • Chart Sales Value and Volume of Lierning in China, 2016-2020
  • Chart Sales Value and Volume of Shengaoding in China, 2016-2020
  • Chart Sales Value and Volume of Anli in China, 2016-2020
  • Chart Referential Prices of SANDOSTATIN in China by Region, 2020-2021
  • Chart Referential Prices of SANDOSTATIN LAR in China by Region, 2020-2021
  • Chart Referential Prices of Lierning in China by Region, 2020-2021
  • Chart Referential Prices of Shengaoding in China by Region, 2020-2021
  • Chart Referential Prices of Anli in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Octreotide Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Octreotide Injection in China, 2021-2025
RSS
Follow by Email